text
"['\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 12월 31일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n한올바이오파마(주)\n상장\n2015.07.30\n경영참여\n116,111,366\n16,115,745\n31.79\n116,111,366\n-\n-\n-\n16,115,745\n31.79\n116,111,366\n236,529,768\n3,858,749\n힐리언스\n비상장\n2006.03.30\n경영참여\n27,310,924\n2,853,300\n78.73\n15,620,220\n-\n-\n-\n2,853,300\n78.73\n15,620,220\n31,411,654\n864,191\nDaewoong Pharma PHILIPPINES, INC.\n비상장\n2007.04.12\n경영참여\n260,539\n-\n100.00\n260,539\n-\n-\n-\n-\n100.00\n260,539\n3,251,521\n153,435\nDaewoong Pharmaceutical(Thailand)Co.,Ltd\xa0\n비상장\n2007.08.22\n경영참여\n205,389\n-\n100.00\n205,389\n-\n-\n-\n-\n100.00\n205,389\n2,425,184\n258,256\nPT. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA\xa0\n비상장\n2006.04.01\n경영참여\n7,812,111\n30,825,649\n100.00\n27,865,665\n9,276,512\n8,072,423\n-\n40,102,161\n100.00\n35,938,088\n34,683,360\n433,321\nDAEWOONG PHARMACEUTICAL HONGKONG\xa0\n비상장\n2013.08.05\n경영참여\n17,660,725\n269,255,424\n89.83\n37,184,429\n-\n-\n-\n269,255,424\n89.83\n37,184,429\n49,320,214\n-17,913\n북경대웅위업의약과기유한공사\n비상장\n2007.08.16\n경영참여\n9,152,033\n-\n100.00\n5,827,683\n-\n-\n-\n-\n100.00\n5,827,683\n1,462,345\n-506,661\n(주)바이오시네틱스\n비상장\n2013.05.19\n공동연구추진\n2,000,000\n645,000\n17.96\n-\n-\n-\n-\n645,000\n17.96\n-\n799,739\n99,384\n(주)이피피미디어\xa0\n비상장\n2008.01.25\n사업목적\n1,000,000\n100,000\n20.00\n-\n-\n-\n-\n100,000\n20.00\n-\n6,295,190\n-36,324\n(주)엠디웰아이엔씨\n비상장\n2007.07.18\n경영참여\n500,000\n100,000\n50.00\n500,000\n-100,000\n-500,000\n-\n-\n-\n-\n12,625,732\n-973,493\nDaewoong America, Inc.\n비상장\n2009.12.30\n경영참여\n825,005\n-\n100.00\n83,287\n-\n-\n-\n-\n100.00\n83,287\n41,256\n-5,591\nDaewoong Pharmaceutical India Pvt.,Ltd\xa0\n비상장\n2013.02.01\n경영참여\n550,733\n-\n100.00\n550,733\n-\n-\n-\n-\n100.00\n550,733\n1,980,375\n-437,856\nDAEWOONG PHARMACEUTICAL JAPAN CO.,LTD\n비상장\n2017.03.08\n경영참여\n555,621\n1,100\n100.00\n555,621\n-\n-\n-\n1,100\n100.00\n555,621\n3,043,972\n510,476\n건강한삶기술창업벤처PEF\xa0\n비상장\n2018.03.19\n사업목적\n2,500,000\n2,500,000,000\n49.50\n2,500,000\n-\n-\n-\n2,500,000,000\n49.50\n2,500,000\n4,452,077\n-49,777\n㈜다나아데이터\n비상장\n2018.11.23\n경영참여\n5,100,000\n102,000\n51.00\n5,100,000\n-\n-\n-\n102,000\n100.00\n5,100,000\n5,433,857\n80,440\nImmplacate, Inc.\n비상장\n2019.03.08\n공동연구추진\n1,125,970\n1,428,571\n20.00\n228,856\n-\n-\n-\n1,428,571\n20.00\n228,856\n108,608\n-43,528\n(주)아피셀테라퓨틱스\n비상장\n2020.01.23\n경영참여\n1,960,780\n3,796,216\n62.14\n10,815,050\n-\n-\n380,530\n3,796,216\n54.78\n11,195,580\n25,005,970\n-9,990,288\n(주)아이엔테라퓨틱스\n비상장\n2020.05.27\n경영참여\n3,118,330\n19,115,085\n93.91\n8,118,330\n-\n-\n-\n19,115,085\n93.91\n8,118,330\n16,607,291\n-14,596,674\nDaewoong Innovation Holdings\n비상장\n2021.07.14\n경영참여\n-\n-\n100.00\n2,355,900\n-\n-\n-\n-\n100.00\n2,355,900\n3,160,364\n446,794\nEvolus.INC(해외상장)\n상장\n2021.03.23\n사업목적\n-\n3,136,869\n5.75\n29,854,908\n-\n-\n12,735,559\n3,136,869\n5.75\n42,590,467\n243,694\n-79,536\n진켐\n비상장\n2000.04.01\n공동연구추진\n559,660\n41,932\n0.46\n177,624\n-\n-\n-\n41,932\n0.46\n177,624\n32,125,848\n-9,877,690\n바이오넷\n비상장\n2001.12.22\n사업목적\n1,207,646\n324,480\n1.95\n227,136\n-\n-\n-\n324,480\n1.95\n227,136\n16,492,299\n-4,299,256\n큐어컴퍼니(주4)\n비상장\n2009.07.01\n공동연구추진\n217,377\n31,110\n1.24\n24,574\n-\n-\n-\n31,110\n1.24\n24,574\n7,859,739\n-3,161,128\n3-D Matrix (해외상장)(주2)\n상장\n2010.09.01\n사업목적\n1,362,230\n320,000\n1.49\n939,455\n-\n-\n-530,582\n320,000\n1.49\n408,873\n71,368,014\n-32,428,967\n카이페리온\n비상장\n2019.10.16\n사업목적\n1,000,020\n28,572\n2.63\n1,000,020\n-\n-\n-\n28,572\n2.63\n1,000,020\n4,770,747\n-669,831\nJTBC(주4)\n비상장\n2011.04.01\n사업목적\n3,000,000\n600,000\n0.52\n419,400\n-\n-\n-\n600,000\n0.52\n419,400\n382,200,727\n14,600,000\n향남제약공단\n비상장\n2005.11.10\n일반참여\n217,879\n-\n-\n217,879\n-\n-\n-\n-\n-\n217,879\n10,653,690\n1,281\n자일자동차판매\n비상장\n2011.12.01\n일반참여\n827,695\n93,286\n0.45\n115,208\n-\n-\n-115,208\n93,286\n0.45\n-\n294,370,125\n-23,931,359\n대우산업개발(주4)\n비상장\n2012.06.05\n일반참여\n592,014\n33,296\n0.43\n401,150\n-\n-\n-401,150\n33,296\n0.43\n-\n284,886,115\n-31,346,622\n인벤티지랩\n상장\n2020.04.28\n기술성투자\n999,995\n83,326\n1.17\n814,928\n-\n-\n634,944\n83,326\n1.17\n1,449,872\n45,182,342\n-26,994,167\n(주)입셀\n비상장\n2020.09.09\n기술성투자\n2,000,002\n9,091\n9.09\n2,000,002\n7,053\n2,999,852\n-\n16,144\n9.09\n4,999,854\n12,999,381\n-10,355,673\n데일리 임파워링 바이오 헬스케어 펀드4호\n비상장\n2020.09.23\n사업목적\n1,000,000\n1,000\n6.83\n863,481\n-\n-\n-\n1,000\n6.83\n863,481\n9,777,600\n-1,282,673\n유안타 퀀텀점프 3호 투자조합\n비상장\n2021.09.10\n사업목적\n-\n1,000\n14.29\n1,000,000\n-\n-\n-\n1,000\n14.29\n1,000,000\n6,706,819\n-152,297\n티온랩테라퓨틱스\n비상장\n2021.07.21\n사업목적\n-\n97,109\n14.78\n738,999\n21,903\n500,001\n-\n119,012\n14.78\n1,239,000\n1,652,245\n-820,322\n서울의료정보연구소(주4)\n비상장\n2020.12.11\n사업목적\n200,063\n1,067\n6.08\n200,063\n-\n-\n-\n1,067\n6.08\n200,063\n945,474\n406,305\nNurron Pharmaceuticals INC.\n비상장\n2021.09.10\n공동연구추진\n-\n58,343\n2.37\n570,549\n-\n-\n-\n58,343\n2.21\n570,549\n3,081,171\n-823,218\nNeurogastrx\n비상장\n2021.06.18\n사업목적\n-\n4,782,095\n5.00\n3,968,422\n-\n-\n-3,461,871\n4,782,095\n2.30\n506,551\n15,637,785\n-20,511,198\n온코크로스\n비상장\n2021.04.01\n공동연구추진\n-\n79,284\n0.90\n1,000,036\n-\n-\n-\n79,284\n0.90\n1,000,036\n16,752,105\n-5,990,833\n넥스아이\n비상장\n2021.12.08\n공동연구추진\n-\n11,705\n4.35\n999,958\n-\n-\n-\n11,705\n4.35\n999,958\n9,172,853\n-13,672,918\n씨어스테크놀로지\n비상장\n2021.12.22\n사업목적\n-\n8,284\n3.16\n5,000,057\n-\n-\n-\n8,284\n3.16\n5,000,057\n17,146,655\n-9,916,946\n미래에셋-현대중공업 신성장투자조합1호\n비상장\n2021.11.01\n사업목적\n-\n400\n5.97\n400,000\n400\n400,000\n-\n800\n5.97\n800,000\n12,248,757\n-591,065\n에버그린투자파트너스4호펀드\n비상장\n2021.11.17\n사업목적\n-\n600\n2.32\n600,000\n200\n200,000\n-\n800\n2.32\n800,000\n31,897,367\n-1,727,276\n브이원바이오\n비상장\n2021.11.30\n사업목적\n-\n21,667\n8.86\n390,006\n-\n-\n-\n21,667\n8.86\n390,006\n246,531\n-269,546\n엑소스템텍\n비상장\n2021.12.30\n공동연구추진\n-\n38,865\n1.40\n999,996\n-\n-\n-\n38,865\n1.40\n999,996\n4,431,250\n-1,241,311\n베어리버(주3)\n비상장\n2022.03.31\n일반참여\n-\n59,520\n0.62\n297,600\n-\n-\n-\n59,520\n0.62\n297,600\n115,380,492\n-9,845,918\n핀테라퓨틱스\n비상장\n2022.02.17\n공동연구추진\n-\n6,329\n1.25\n999,982\n-\n-\n-\n6,329\n1.25\n999,982\n3,417,398\n-11,877,862\n디시젠\n비상장\n2022.04.22\n사업목적\n-\n256\n1.59\n1,001,351\n-\n-\n-\n256\n1.59\n1,001,351\n7,528,044\n-3,755,108\n시너지에이아이\n비상장\n2022.04.29\n공동연구추진\n-\n7,000\n2.94\n499,996\n-\n-\n-\n7,000\n2.94\n499,996\n1,291,824\n-229,226\n메디아이오티\n비상장\n2022.05.13\n공동연구추진\n-\n629\n3.99\n199,709\n-\n-\n-\n629\n3.99\n199,709\n524,721\n-555,697\n켈스\n비상장\n2022.10.05\n사업목적\n-\n92,592\n2.24\n999,993\n-\n-\n-\n92,592\n2.24\n999,993\n12,499,692\n-4,677,227\n차세대 지역 뉴딜&바이오투자조합\n비상장\n2022.10.28\n사업목적\n-\n600\n10.00\n600,000\n800\n800,000\n-\n1,400\n10.00\n1,400,000\n13,598,883\n-8\n셀타스퀘어\n비상장\n2022.11.14\n공동연구추진\n-\n20,000\n4.76\n400,000\n-\n-\n-\n20,000\n4.76\n400,000\n1,062,389\n-478,394\n에피바이오텍\n비상장\n2022.12.22\n공동연구추진\n-\n78,947\n2.62\n1,499,993\n-\n-\n-\n78,947\n2.62\n1,499,993\n9,524,102\n-1,057,434\n이모티브\n비상장\n2022.12.26\n공동연구추진\n-\n685\n1.16\n159,810\n-\n-\n-\n685\n1.16\n159,810\n2,650,260\n-732,375\n휴먼스케이프\n비상장\n2022.10.21\n사업목적\n-\n2,799\n1.97\n1,999,986\n-\n-\n-\n2,799\n1.97\n1,999,986\n28,559,485\n-15,534,351\n셀라톡스바이오파마\n비상장\n2022.12.28\n경영참여\n-\n990\n99.00\n802,824\n53,727\n46,238,815\n-\n54,717\n99.36\n47,041,639\n49,454,451\n-572,804\n바이옴에이츠\n비상장\n2023.03.22\n공동연구추진\n-\n-\n-\n-\n901\n300,033\n-\n901\n3.34\n300,033\n1,428,526\n-749,315\nAlloplex\n비상장\n2023.01.27\n공동연구추진\n-\n-\n-\n-\n9,794\n827,338\n-\n9,794\n0.27\n827,338\n6,594,491\n-4,296,075\nVITALLI BIO, INC\n비상장\n2023.05.30\n공동연구추진\n-\n-\n-\n-\n2,098,132\n5,356,406\n-\n2,098,132\n16.67\n5,356,406\n19,247,395\n-1,315,418\nAeon Biopharma, Inc.(해외상장)\n상장\n2023.07.22\n공동연구추진\n-\n-\n-\n-\n2,400,000\n32,931,052\n-10,650,220\n2,400,000\n6.46\n22,280,832\n8,825\n-48,308\n라이플렉스 사이언스\n비상장\n2023.10.18\n사업목적\n-\n-\n-\n-\n209,938\n300,001\n-\n209,938\n5.66\n300,001\n995,679\n-224,004\n살루스케어\n비상장\n2023.12.27\n사업목적\n-\n-\n-\n-\n5,250\n4,999,995\n-\n5,250\n4.76\n4,999,995\n6,527,967\n351,355\n대웅인베스트먼트 바이오투자조합 1호\n비상장\n2023.07.19\n사업목적\n-\n-\n-\n-\n400\n400,000\n-\n-\n10.00\n400,000\n3,925,272\n-201,945\nFREEMIND INVESTMENTS LP\n비상장\n2023.06.26\n사업목적\n-\n-\n-\n-\n-\n660,800\n-\n-\n24.75\n660,800\n2,611,285\n-\n대웅이엔지\n비상장\n2023.07.14\n경영참여\n-\n-\n-\n-\n71,180\n479,951\n-\n-\n100.00\n479,951\n6,145,837\n-22,205\n한국제약협동조합\n비상장\n2013.01.18\n일반참여\n-\n-\n-\n12,600\n-\n629,138\n-\n-\n-\n641,738\n6,291,548\n-116,241\nTurn Biotechnologies(주4)\n비상장\n2023.08.22\n공동연구추진\n-\n-\n-\n-\n733,036\n824,443\n-\n733,036\n1.45\n824,443\n4,301,682\xa0\n-16,491,502\n뷰브레인헬스케어\n비상장\n2023.10.06\n공동연구추진\n-\n-\n-\n-\n1,629\n999,554\n-\n1,629\n5.99\n999,554\n2,002,053\n-1,464,368\n합 계\n-\n-\n296,280,763\n14,790,855\n107,419,802\n-1,407,998\n-\n-\n402,292,567\n2,037,060,108\n-278,983,736\n(주1) 상기 최근사업연도 재무현황은\xa023년 기말 재무제표 기준입니다.\n(주2) 3D Matrix는\xa04월 결산법인으로\xa02023년\xa04월말 기준 재무제표입니다.\n(주3) 베어리버의 회생계획인가에 따라 취득한 주식입니다.\n(주4) 재무현황은\xa022년 기말 재무제표 기준입니다.[출자목적 세부 내용]\n법인명\n출자목적\n세부 목적\n큐어컴퍼니\n공동연구 추진\n폐암치료제 공동 R&D\nNurron\n공동연구 추진\n파킨슨 치료제 개발 업체 투자\n넥스아이\n공동연구 추진\n파이프라인 공동연구 개발\nImmplacate, Inc.\n공동연구 추진\n줄기세포치료제 공동연구/개발\n바이오시네틱스\n공동연구 추진\n나노기술 활용 신약개발\n온코크로스\n공동연구 추진\n공동연구 및 양사 협력관계 강화\n엑소스템텍\n공동연구 추진\nDW-MSC 엑소좀 파이프라인 확장/MOU 체결\n진켐\n공동연구 추진\nAnti-Sense 항암제 등 공동 R&D\n인벤티지랩\n기술성 투자\n장기지속형 주사제 파이프라인 발굴\n입셀\n기술성 투자\n유망 파이프라인 선확보\n브이원바이오\n사업목적\n마이크로바이옴 연구협력\n티온랩테라퓨틱스\n사업목적\n서방형 데포치료제 연구협력\nNeurogastrx\n사업목적\n펙수프라잔 미국 L/O 대금 일부에 대한 지분 취득\n씨어스\n사업목적\n패치형 심전도기/병상모니터링 관련 사업협업\nEvolus.INC(해외상장)\n사업목적\n파트너 재무구조 개선 및 파트너십 강화\nJTBC\n사업목적\n우호적인 종편채널 확보\n카이페리온\n사업목적\n신사업 O/C 강화\n서울의료정보연구소\n사업목적\n보건의료데이터 사업분야 전략적 협업\n바이오넷\n사업목적\n내시경 등 의료기기 사업 투자\n자일자동차판매\n일반참여\n투자수익 창출\n대우산업개발\n일반참여\n투자수익 창출\n3-D Matrix (해외상장)\n사업목적\n흡수성 국소지혈제 국내 판권 확보\n에버그린투자파트너스4호펀드\n사업목적\n연구개발 스타트업 발굴\n미래에셋-현대중공업 신성장투자조합1호\n사업목적\n중장기 미래 파이프라인 동력 및 네트워크 확보\n데일리 임파워링 바이오 헬스케어 펀드4호\n사업목적\n바이오 기업 발굴 등 신사업 O/C 강화\n유안타 퀀텀점프 3호 투자조합\n사업목적\n목적펀드 내 투자회사와의 글로벌 사업 진출 협력\n건강한삶기술창업벤처PEF\xa0\n사업목적\n펀드참여\n메디아이오티\n공동연구추진\n이노베어 공모전 당선 회사로 협력모델 확보\n시너지 A.I.\n공동연구추진\n모비케어 차세대 제품개발 및 마케팅 파트너\nDC Gen\n사업목적\n온코프리(유방암 진단 키트) 글로벌 사업협력\n핀테라퓨틱스\n공동연구추진\n단백질분해(TPD) 신약개발 역량확보\n켈스\n사업목적\n신속항원 진단키트 등 사업 협력\n휴먼스케이프\n사업목적\n디지털 헬스케어 플랫폼 연계/협력\n차세대 지역 뉴딜&바이오투자조합\n사업목적\n중장기 미래 파이프라인 동력 및 네트워크 확보\n셀타스퀘어\n공동연구추진\n임상PV 솔루션 효율성 증대 등 SI협력\n에피바이오텍\n공동연구추진\n세포치료제 공동 연구개발\n이모티브\n공동연구추진\n디지털치료제 연구개발 및 사업 협력\nAlloplex\n공동연구추진\n항암 세포치료제 상업화 협력\n바이옴에이츠\n공동연구추진\n복합균주 공동 연구개발\nVITALLI BIO, INC\n공동연구추진\n자가면역 치료 신약후보물질 기술수출\nAeon Biopharma, Inc.\n공동연구추진\n파트너 재무구조 개선 및 파트너십 강화\n라이플렉스 사이언스\n공동연구추진\nASO 기반 연구개발 협력\n살루스케어\n사업목적\n보건의료데이터 사업분야 전략적 협업\nFREEMIND INVESTMENTS LP\n사업목적\n목적펀드 내 투자회사와의 글로벌 사업 진출 협력\nTurn Biotechnologies\n공동연구추진\nLNP 플랫폼 공동 연구개발\n뷰브레인헬스케어\n공동연구추진\n치매 조기진단 및 치료제 연구개발 협력\n[장부가액 감액 사유]\n(단위: 천원)\n법인명\n감액금액\n감액 사유\n3D Matrix\n(530,582)\n공정가치 평가에 따른 감소\n자일자동차판매\n(115,208)\n대우산업개발\n(401,150)\nNeurogastrx\n(3,461,871)\nAeon Biopharma Inc\n(10,650,220)\n']"
